You are welcome! As far as I aware, Tata’s have already bought majority in 1mg.
Also, what I understand, Pharmeasy, via API holdings, is the only big player in digital and organized B2B pharma distribution along with a good B2C interface and if Thyrocare acquisition materialises, then their own diagnostic as well.
btw, as per articles I read in public domain, Pharmeasy plan to do the Thyrocare acquisition before the IPO and they intend to carry on with 2 seperate listed companies subsequently…although all news is fresh potato at the moment…